Welcome to our dedicated page for Bullfrog AI Holdings news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on Bullfrog AI Holdings stock.
BullFrog AI Holdings, Inc. uses artificial intelligence and machine learning to turn complex biomedical data into actionable insights for drug discovery and development. Company news centers on the bfLEAP® platform, data harmonization through bfPREP™, and bfARENAS™, a scenario-based decision engine for pharmaceutical portfolio strategy, target selection, biomarker strategy and clinical trial design.
Recurring updates also cover commercial feasibility agreements with pharmaceutical customers, research-institution collaborations, white papers and conference participation in life sciences and oncology. Corporate news includes Nasdaq continued-listing compliance, at-the-market and equity-line financing activity, balance-sheet updates, and shareholder communications tied to the company’s common stock and tradable warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BullFrog AI Holdings, Inc. (NASDAQ:BFRG; BFRGW) announced the filing of its Form 10-K with the SEC for the year ending December 31, 2022. This filing, essential for compliance, was initially delayed due to the complexities surrounding its first-time submission, which led to a notice from Nasdaq regarding non-compliance with listing requirements. Following this completed filing, the company has restored its compliance. CEO Vin Singh expressed confidence in avoiding future delays. BullFrog AI focuses on precision medicine through machine learning, collaborating with institutions like Johns Hopkins University to enhance drug development using their proprietary bfLEAP™ platform.